These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36294700)

  • 1. The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.
    Maibach HT; Brownstein MJ; Hersch SM; Anderson KE; Itzkowitz DE; Damiano EM; Simon NG
    J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
    Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of the irritability scale in Huntington's disease patients with evidence of irritability or aggression.
    En-Hua Wang J; Simon NG; Brownstein MJ; Maibach HT; Maibach J; Anderson KE
    Parkinsonism Relat Disord; 2024 Jun; 123():106087. PubMed ID: 38640832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study.
    Lee RJ; Coccaro EF; Cremers H; McCarron R; Lu SF; Brownstein MJ; Simon NG
    Front Syst Neurosci; 2013; 7():100. PubMed ID: 24376401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.
    Fabio KM; Guillon CD; Lu SF; Heindel ND; Brownstein MJ; Lacey CJ; Garippa C; Simon NG
    J Pharm Sci; 2013 Jun; 102(6):2033-2043. PubMed ID: 23471831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.
    Difede J; McAleavey AA; Emrich M; Jick A; Ovalles A; Wyka K; Spielman L; Olden M; Peskin M; Becket-Davenport C; Rubenstein A; Brownstein MJ; Damiano E; Itzkowitz D; Lu SF; Needell NJ; Kocsis JH; Gordon-Elliott JS; Simon NG
    Contemp Clin Trials Commun; 2023 Jun; 33():101116. PubMed ID: 37008794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural brain correlates of irritability and aggression in early manifest Huntington's disease.
    Martinez-Horta S; Sampedro F; Horta-Barba A; Perez-Perez J; Pagonabarraga J; Gomez-Anson B; Kulisevsky J
    Brain Imaging Behav; 2021 Feb; 15(1):107-113. PubMed ID: 31898092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
    Lago TR; Brownstein MJ; Page E; Beydler E; Manbeck A; Beale A; Roberts C; Balderston N; Damiano E; Pineles SL; Simon N; Ernst M; Grillon C
    Psychopharmacology (Berl); 2021 Sep; 238(9):2393-2403. PubMed ID: 33970290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.
    Weiner MF; Koss E; Patterson M; Jin S; Teri L; Thomas R; Thal LJ; Whitehouse P
    J Psychiatr Res; 1998; 32(6):347-51. PubMed ID: 9844950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and Validity of a Chinese Version of the Cohen-Mansfield Agitation Inventory-Short Form in Assessing Agitated Behavior.
    Sun FC; Lin LC; Chang SC; Li HC; Cheng CH; Huang LY
    Int J Environ Res Public Health; 2022 Aug; 19(15):. PubMed ID: 35954767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritability in Huntington's Disease.
    Karagas NE; Rocha NP; Stimming EF
    J Huntingtons Dis; 2020; 9(2):107-113. PubMed ID: 32417789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
    Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
    Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington's disease.
    McLauchlan DJ; Linden DEJ; Rosser AE
    Front Neurosci; 2022; 16():993357. PubMed ID: 36643017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior.
    Ferris CF; Lu SF; Messenger T; Guillon CD; Heindel N; Miller M; Koppel G; Robert Bruns F; Simon NG
    Pharmacol Biochem Behav; 2006 Feb; 83(2):169-74. PubMed ID: 16504276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Taking Behaviors in Huntington's Disease.
    McDonell KE; Ciriegio AE; Pfalzer AC; Hale L; Shiino S; Riordan H; Moroz S; Darby RR; Compas BE; Claassen DO
    J Huntingtons Dis; 2020; 9(4):359-369. PubMed ID: 33164940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's Disease: Prevalence and Psychological Indicators of Pain.
    Underwood M; Bonas S; Dale M;
    Mov Disord Clin Pract; 2017; 4(2):198-204. PubMed ID: 30363479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia.
    Acharya D; Harper DG; Achtyes ED; Seiner SJ; Mahdasian JA; Nykamp LJ; Adkison L; Van der Schuur White L; McClintock SM; Ujkaj M; Davidoff DA; Forester BP
    Int J Geriatr Psychiatry; 2015 Mar; 30(3):265-73. PubMed ID: 24838521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.